IoT is advancing at full speed, what do we do about cybersecurity?
The positive aspects of this technology are many and varied, but there are also some risks that would be wise to keep in check.
Russell Howard is an experienced CEO who has led several successful life-sciences and biotechnology companies, both private and public. He has published over 140 peer-reviewed scientific publications and serves on the board of several companies and foundations in the U.S. and overseas. Today Russell works in Sydney with NeuClone, dedicated to bringing affordable biosimilar monoclonal antibodies to the world, and Genome. One where whole genome sequencing is being commercialised to provide new products and services based on personalised medicine.
